Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus

被引:56
作者
Huang, Jiaying
Smirnov, Sergey V.
Lewis-Antes, Anita
Balan, Murugabaskar
Li, Wei
Tang, Sheila
Silke, Gemma V.
Putz, Mike M.
Smith, Geoffrey L.
Kotenko, Sergei V. [1 ]
机构
[1] Univ Hosp, New Jersey Med Sch, Ctr Canc, Dept Biochem & Mol Biol, Newark, NJ 07103 USA
[2] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, London W2 1PG, England
基金
英国医学研究理事会; 英国惠康基金;
关键词
antiviral response; interferon antagonists; interferon receptors; poxviruses; virus evasion;
D O I
10.1073/pnas.0610352104
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Type I (IFN-alpha/beta) and type III (IFN-lambda s) IFNs are important components of the host antiviral response. Although type III IFINs possess intrinsic antiviral activity similar to that of type I IFNs, they signal through a specific unique receptor complex, and their functional importance for antiviral resistance is largely uncharacterized. Here, we report the first virus defense mechanism that directly targets type III IFINs. Y136 from Yaba-like disease virus, a yatapoxvirus, is a secreted glycoprotein related to protein 1318 from Vaccinia virus, a known type III IFN-binding protein and a member of the Ig superfamily. Surprisingly, whereas B18 inhibits only type I IFNs, Y136 inhibits both type I and type III IFNs. Y136 inhibits IFN-induced signaling and suppresses IFIN-mediated biological activities including up-regulation of MHC class I antigen expression and induction of the antiviral state. These data demonstrate that poxviruses have developed unique strategies to counteract IFN-mediated antiviral protection and highlight the importance of type III IFNs in antiviral defense. These results suggest that type III IFNs may be an effective treatment for some poxviral infections.
引用
收藏
页码:9822 / 9827
页数:6
相关论文
共 32 条
[1]  
ALCAMI A, 1995, J VIROL, V69, P4633
[2]   The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN [J].
Alcamí, A ;
Symons, JA ;
Smith, GL .
JOURNAL OF VIROLOGY, 2000, 74 (23) :11230-11239
[3]   Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo [J].
Ank, N ;
West, H ;
Bartholdy, C ;
Eriksson, K ;
Thomsen, AR ;
Paludan, SR .
JOURNAL OF VIROLOGY, 2006, 80 (09) :4501-4509
[4]   IFN-λ:: Novel antiviral cytokines [J].
Ank, Nina ;
West, Hans ;
Paludan, Soren R. .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2006, 26 (06) :373-379
[5]  
[Anonymous], 2007, POXVIRUSES, DOI [10.1007/978-3-7643-7557-7, DOI 10.1007/978-3-7643-7557-7, DOI 10.1007/978-3-7643-7557-7_6]
[6]   Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model [J].
Bartlett, NW ;
Buttigieg, K ;
Kotenko, SV ;
Smith, GL .
JOURNAL OF GENERAL VIROLOGY, 2005, 86 :1589-1596
[7]  
CHEN J, 2003, Patent No. 6300475
[8]   VACCINIA VIRUS B18R GENE ENCODES A TYPE-I INTERFERON-BINDING PROTEIN THAT BLOCKS INTERFERON-ALPHA TRANSMEMBRANE SIGNALING [J].
COLAMONICI, OR ;
DOMANSKI, P ;
SWEITZER, SM ;
LARNER, A ;
BULLER, RML .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (27) :15974-15978
[9]   Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes [J].
Doyle, Sean E. ;
Schreckhise, Heidi ;
Khuu-Duong, Kien ;
Henderson, Katherine ;
Rosler, Robert ;
Storey, Harold ;
Yao, Lena ;
Liu, Hong ;
Barahmand-pour, Fariba ;
Sivakumar, Pallavur ;
Chan, Chung ;
Birks, Carl ;
Foster, Don ;
Clegg, Christopher H. ;
Wietzke-Braun, Perdita ;
Mihm, Sabine ;
Klucher, Kevin M. .
HEPATOLOGY, 2006, 44 (04) :896-906
[10]   Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-λ1 -: Similarities with type I interferon signaling [J].
Dumoutier, L ;
Tounsi, A ;
Michiels, T ;
Sommereyns, C ;
Kotenko, SV ;
Renauld, JC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (31) :32269-32274